Hello! 🔬👨🔬
In this review @Andrea-Loreto.bsky.social and I discuss the breadth of therapeutic potential for the neurodegenerative enzyme SARM1
- Challenges for SARM1 therapeutic inhibition
- SARM1 in non-neuronal cells
- SARM1 activation for selective peripheral neuroablation.
www.cell.com/trends/pharm...
💉👀 Ozempic. What does the eye have to do with it?
Let’s take a look at the latest evidence published in @jamanetworkopen.com
Thank you to @aunz.theconversation.com for inviting me to write this piece. Was a pleasure to write with @petetheteapot.bsky.social from @ki.se
Dr Pete Williams @petetheteapot.bsky.social @ki.se will be our next webinar speaker!
'From bench to bedside and back again: Targeting NAD for neuroprotection in #glaucoma'
Aug 11, 2025
10-11am ET
Host: Dr Diane Bovenkamp @dianebovenkamp.bsky.social @brightfocus.bsky.social
Register: bit.ly/4o6WrqY
Doing science today feels like playing a video game on legendary difficulty.
With shrinking budgets, extreme publication fees, subjective rejections, and daily lab chaos, the path of a scientist is tougher than ever.
At least we have Parafilm to hold it all together.
Stay strong, scientists.
Breaking News: A baby with a rare disorder made medical history by receiving the first custom gene-editing treatment. The technique used has the potential to help people with thousands of other uncommon genetic diseases. nyti.ms/4j49xBy
'we define how mitochondrial gene expression is spatially organized at sub-organellar scales into regulatory hubs that are subject to stress-induced remodeling. We propose that this remodeling into mitochondrial stress bodies may serve to aid in recovery of mitochondrial proteome quality control'
“The visa fees are so exceedingly high that it makes coming here very difficult for some people. We are fishing for the best scientists in the world. They want to come and work here because we are such an effective country at science, but if we have these high costs, they can and will go elsewhere.”
Monitoring in real time and far-red imaging of H2O2 dynamics with subcellular resolution www.nature.com/articles/s41...
Remember to pick up your EyeVenture pins today. Collect 7 different ones during #ARVO2025, bring them to @arvoinfo.bsky.social Central by May 8 and you could win free registration to #ARVO2026 in Denver, Colo.! Check our website for today's collection locations. bit.ly/2GErnw4
The authors of a Comment article in Nature write that hopes are high that AI can accelerate scientific discovery but warn that the rush to adopt AI has consequences. “Establishing clear scientific guidelines on how to use these tools and techniques is urgent.” 🧪
Meta used at least 16 of my books, and numerous articles, to help train the AI it will use to make billions.
Authors, search your name here:
www.theatlantic.com/technology/a...
New publication out with Katharina C Bell, Vicki Chrysostomou, Markus Karlsson, myself, Pete A Williams @petetheteapot.bsky.social , and Jonathan G Crowston
Excitatory and Inhibitory Neurotransmitter Alterations With Advancing Age and Injury in the Mouse Retina
bryanwjones.com/2025/03/exci...
"What they have done is, frankly, destroy trust and good will within the university."
@leightonandrews.bsky.social
www.bbc.co.uk/news/article...
Why academia is sleepwalking into self-destruction. My editorial @brain1878.bsky.social If you agree with the sentiments please repost. It's important for all our sakes to stop the madness
academic.oup.com/brain/articl...
* snort *
My favorite thing about journal editors in the upper echelons of impact is that they deem my manuscripts of not being of sufficient quality or impact for their journal, but within the same week they are very happy to have me as a reviewer to judge said quality...
What a fun review to write with @petetheteapot.bsky.social on metabolic dysfunction in glaucoma! It’s out today in Glaucoma Today 😆 enjoy the read at the link below🧪 #glaucoma
glaucomatoday.com/articles/202...
"[The] findings indicate that young children with AIPL1-related retinal dystrophy benefited substantially from subretinal administration of rAAV8.hRKp.AIPL1, with improved visual acuity and functional vision and evidence of some protection against progressive retinal degeneration [...]."
Another success for gene therapy!
From The Lancet: Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study
www.thelancet.com/journals/lan...
#ophthalmology #genetherapy
@
Putting the brakes on mitochondrial fusion to prevent escape of mitochondrial DNA
www.nature.com/articles/d41...
Nice opinion piece by @adamsobel.bsky.social about destruction of U.S. science.
thebulletin.org/2025/02/how-...
Hate that it has come to this, but it's time to consider PubMed vulnerable to enshittification. My latest post @plos.org discusses the lines we need to fight to hold – and alternatives we can rely on internationally:
absolutelymaybe.plos.org/2025/02/14/w...
#medlibs
Bingo. F&A (equivalent of our SA + INDI + rent) is additive to the direct (research costs). Which is a pretty good gig when an R01 maxes out at 500k (5 MSEK) a year (not that everyone gets funded at the top level).
I've been itching to post this with fear of being canceled haha!
100% agree. The powerful thing with the NIH is overheads AFTER research budget, not as part of.
Imagine how far our KI money would go if we didn't lose 20-25% in admin + rent + 55% on social security ...
Hello Vision Science Peeps!
Be sure to put the @iser.bsky.social / @brightfocus.bsky.social Concepts and Breakthroughs In Glaucoma Meeting on your schedule. It will be in Atlanta, Georgia, USA from October 8-11, 2025
iserbrightfocusglaucoma.org
The Howard Hughes Medical Institute, the nation’s largest private funder of biomedical research, yesterday killed a $60 million program aimed at making universities’ STEM education more inclusive. scim.ag/3EtS0US
IMAX only right now. I need it on streaming ASAP !
Super cool new review by @caromenard666.bsky.social’s team on neuro-glio-vascular alterations #cerebrovascular
Are you sure Maine wants you back haha!